For many years, my standard approach has be either topotecan or paclitaxel. I actually prefer paclitaxel over topotecan for patients with rapid progression after first line therapy. In refractory patients, the RR with topotecan in trials is only about 10% (which seems about right from my practice), ...

My standard approach for treating patients with platinum refractory small cell lung cancer, outside a clinical trial, is to offer oral topotecan. While this treatment has limited efficacy, it is the only therapy that has demonstrated a survival advantage in this patient population. Nivolumab pl...

Platinum refractory small cell lung cancer patients have a poor prognosis, and despite the limited data (CheckMate 032), I do consider ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) for patients with very good performance status, having had a few of my patients on & off trial respond. ASCO 2017 j...

The approved second-line option topotecan provides limited benefits and can be associated with significant hematologic toxicities. The updated data from the nonrandomized cohort from Checkmate 032 presented at ASCO 2017 showed that single-agent nivolumab and nivolumab in combination with ipilumumab ...